WuXi AppTec (Stock Code: 603259.SH/2359.HK) provides comprehensive, integrated new drug R&D and manufacturing services for the global biopharmaceutical industry. By empowering global pharmaceutical, biotechnology and medical device companies, WuXi AppTec is committed to advancing the new drug R&D process and bringing breakthrough therapeutic solutions to patients. With the purpose of putting research first and being customer-centric, WuXi AppTec helps customers improve R&D efficiency through cost-effective and efficient R&D services. Its service scope covers chemical drug R&D and manufacturing, cell and gene therapy R&D and manufacturing, medical device testing and other fields. At present, WuXi AppTec's enabling platform is carrying R&D innovation projects from more than 5,200 partners in over 30 countries around the world, committed to bringing more new drugs and good drugs to patients worldwide and realizing the vision of "making it possible for anyone to develop drugs and treat diseases" as soon as possible.
The WuXi AppTec Changshu site was established in November 2019, and the workshop achieved trial operation in 2022. The Changshu site is another newly built production technology platform, undertaking the growing scale-up business needs of WuXi AppTec for APIs, intermediates and CMC projects.
What does Wuxi AppTec New Drug Development (Changshu) Co., Ltd. require? Who is Wuxi AppTec New Drug Development (Changshu) Co., Ltd. hiring? recruitment: Skilled Worker占比最多占41.6%,其次是Factory Production占37.7%. What education can get in at ? 本科占比最多占63.6%,其次是高中占13%. High education required at ? 硕士占7.8%. Work experience required at ? 不限占比最多占48.1%,其次是3-5年占22.1%. Where are the job locations at ? 苏州占比最多占100%. Based on job postings from the past year, for reference only.
Congratulations, submitted successfully!
Your edit is under review. You will be notified by email within 1 business day.
Submission failed.
Help others learn about this company, add my impression of this company»
Log in with the following accounts to save your follows